Biologics have undoubtedly revolutionized treatment, but there is a downside – cost. The complex manufacturing processes and quality control required to develop safe and effective biopharmaceutical drugs often result in expensive final products. Therefore, there is a large demand for approved biologics that are less costly but therapeutically equivalent.
Given the highly competitive field of biosimilars, many companies are making inroads into biobetters. A biobetter addresses the same targets as existing biopharmaceuticals, and usually through the same mode of action, but aims to provide improvements. "Better" can be achieved by making structural changes to the original biologic, such as chemical modification, amino acid changes or protein fusion.
With the rapid expected growth in the biobetters market, Creative Biolabs believes that our ADCC / CDC enhancement technology has the potential to become a safe and efficient expression tool, which can help accelerate the development and production of biobetter therapeutic antibodies on a flexible commercial scale. Explore more of our: ADCC Enhancement Technology, CDC Enhancement Technology.
Creative Biolabs provides best-in-class biobetter products, including:
ADCC-Enhanced Biobetters
ADCC-Enhanced antibodies represent a next-generation class of therapeutic antibodies engineered to optimize immune-mediated tumor cell destruction. By leveraging the power of antibody-dependent cellular cytotoxicity (ADCC), these antibodies are specifically designed to engage immune effector cells more effectively, leading to enhanced tumor cell killing.
CDC-Enhanced Biobetters
Cdc-enhanced antibodies represent a breakthrough class of therapeutic biologics designed to harness the full potential of the immune system’s complement cascade. By precisely engineering the Fc region, Creative Biolabs introduces a new era of antibody therapies that are optimized for enhanced complement-dependent cytotoxicity (CDC).
Recombinant Immunotoxins (RITs)
Antibody therapy has become an important part of the treatment of malignant diseases. Antibodies can block tumor growth factors or their receptors, activate immune attacks on tumors, and are used to deliver payloads such as radioisotopes, cytotoxic drugs, or toxins.
Cell-Based Bioassay
Creative Biolabs has long-term experience in the detection of cell-based monoclonal antibody (mAb) therapeutics. Our scientific research team can provide support for the development, optimization, identification and verification of key bioassays, from simple first-level performance measurement to comprehensive characterization of biological activity of biobetter molecules.
ADCC Cell Line
The clinical efficacy of monoclonal antibodies as cancer therapeutics depends largely on their ability to target tumors and induce functional anti-tumor immune responses. Antibody-dependent cell-mediated cytotoxicity (ADCC) is triggered by the interaction of the Fc portion of the antibody with the Fc receptor on the immune cell.
Glycan Analysis
In addition to the amino acid sequence, the activity of an antibody is also significantly affected by post-translational modifications (PTMs). Among the many PTMs, glycosylation modifications are one of the most important and complex modifications, accounting for more than 50%. Its glycosylation site, type, and abundance may affect the efficacy, safety, and quality stability of the antibody.
Fc Silent Antibody
Fc silence antibody is a therapeutic antibody that achieves a reduction in Fc effector function, such as cytokine release, by mutating Fc regions. Creative Biolabs' best-in-class Fc Engineering technology platform enables you to produce Fc Silence therapeutic antibodies.
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC/CDC-enhanced biobetter antibodies. Our scientists are dedicated to bringing years of valuable therapeutic antibody development experience and expertise to our partner to achieve a meaningful partnership together. With our knowledge of quality control agreements and global regulatory requirements, we can help our partners further their programs with more chance to succeed.
For commercial partners interested in our ADCC/CDC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Search for more products.
...
All products and services are for Research Use Only. Do Not use in humans.
